Shareholders' Equity

Issuances of Common Stock

In December 2017, the Company entered into a securities purchase agreement with an affiliate of Third Security for the private placement of 1,207,980 shares of the Company's common stock for gross proceeds of $13,686.

In August 2015, the Company closed a public offering of 5,609,756 shares of its common stock, the net proceeds of which were $218,193, after deducting underwriting discounts of $11,500 and offering expenses paid by the Company of approximately $306, all of which were capitalized.

In January 2015, the Company closed a public offering of 4,312,500 shares of its common stock, including 555,556 shares of common stock purchased by affiliates of Third Security. The net proceeds of the offering were $110,041, after deducting underwriting discounts and commissions of $6,086 and offering expenses paid by the Company of approximately $311, all of which were capitalized.

Dividends to Shareholders

In January 2017, the Company distributed to its shareholders 1,776,557 shares of AquaBounty common stock valued at $22,385. The distribution constituted a dividend to shareholders of record as of January 9, 2017. In connection with the distribution and pursuant to the terms of the Company's equity incentive plans, the conversion terms of all outstanding options for shares of the Company's common stock as of January 9, 2017 were adjusted to reflect the value of the distribution with respect to shares of the Company's common stock by decreasing the exercise prices and increasing the number outstanding options. This adjustment resulted in 46,766 additional outstanding options at a weighted average exercise price of $31.11.

In June 2015, the Company distributed to its shareholders 17,830,305 shares of ZIOPHARM common stock, representing all of the equity interests of ZIOPHARM held by the Company at the time of the distribution and resulting in a realized gain of $81,401. The distribution constituted a dividend to shareholders of record as of June 4, 2015. In connection with the distribution, pursuant to the terms of the Company's equity incentive plans, the conversion terms of all outstanding options for shares of the Company's common stock as of June 4, 2015 were adjusted to reflect the value of the distribution with respect to shares of the Company's common stock by decreasing the exercise prices and increasing the number of shares. This adjustment resulted in 312,795 additional outstanding options at a weighted average exercise price of $25.40.

Components of Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows:



	December 31,
	2017			2016
Unrealized loss on investments	$	(2	)	$	(89	)
Loss on foreign currency translation adjustments	(15,552		)	(36,113		)
Total accumulated other comprehensive loss	$	(15,554	)	$	(36,202	)